LAD191

Almirall, S.A. · Phase 2 active Small molecule

At a glance

Generic name	LAD191
Sponsor	Almirall, S.A.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Single and Multiple Ascending Dose Study in Healthy Participants and Participants With an Autoimmune Disease (PHASE1)
A Study of LAD191 in Adults With Hidradenitis Suppurativa (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LAD191 CI brief — competitive landscape report
LAD191 updates RSS · CI watch RSS
Almirall, S.A. portfolio CI